Glenmark Pharma wilts 3% on muted Q4 show, CLSA downgrades to sell
Elara Capital which has reduce rating on stock said FY19 operating performance remained weak, given lack of meaningful US sales. Glenmark Pharma shares fell 3 percent intraday on May 31 as global brokerage house CLSA downgraded the stock after March quarter earnings missed analyst estimates. The stock was quoting at Rs 544.40, down Rs 10.95, or 1.97 percent on the BSE at 11:01 hours. The scrip has wilted 15 percent in the last one month. CLSA downgraded Glenmark rating to sell from buy and slashed price target by 32 percent to Rs 500 from Rs 740 after cutting FY20-21 EPS estimates by 22-27 percent. The brokerage said the fourth quarter numbers were below estimates due to a miss on US revenue and Higher R&D/SG&A spends. "We expect the investment phase to remain high over the next two years. High investment phase will keep earnings outlook subdued and benefits of current investments will only reflect FY22 onwards," it added. The drug ma...